BioCentury | Aug 17, 2019
Financial News

Aug. 16 Financial Quick Takes: Trio of IPO filings; plus Bellicum, Generex

SpringWorks, Satsuma, Monopar propose IPOs SpringWorks Therapeutics Inc. (Stamford, Conn.), Satsuma Pharmaceuticals Inc. (South San Francisco, Calif.) and Monopar Therapeutics Inc. (Northbrook, Ill.) are looking to go public on NASDAQ. SpringWorks proposed to raise up...
BioCentury | Jul 12, 2019
Company News

July 12 management tracks: Linus Lin joins Lilly’s Chorus; plus Ocular, Aptinyx

Eli Lilly and Co. (NYSE:LLY) named Linus Lin managing director of its Chorus R&D unit. He was previously VP and head of Lilly China Innovation and Partnerships. Eye disease company Ocular Therapeutix Inc. (NASDAQ:OCUL) hired...
BioCentury | Jul 10, 2019
Company News

Management tracks: Maze, Tiaki, NED, Annexon and more

Maze Therapeutics (Redwood City, Calif.) said Richard Scheller joined its board. Scheller, who in January became chairman of R&D at BridgeBio Pharma Inc. (NASDAQ:BBIO), was CSO and head of therapeutics at personal genetics company 23andMe...
BioCentury | May 20, 2019
Clinical News

May 20 Clinical Quick Takes: Keytruda misses in TNBC; plus Medicines Co., Acadia, Takeda, Ocular

Keytruda fails in previously treated TNBC Monotherapy with PD-1 inhibitor Keytruda pembrolizumab from Merck & Co. Inc. (NYSE:MRK) missed the primary endpoint of improving overall survival vs. physician’s choice of single agent chemotherapy in the...
BioCentury | Apr 6, 2019
Finance

Big caps under pressure

Biogen’s fall in the wake of its decision to discontinue late-stage trials of Alzheimer’s therapy aducanumab is yet another reminder that large caps are in dire need of new pipeline products, and could serve as...
BioCentury | Jan 12, 2019
Finance

We all fall down

After an exuberant third quarter that put biotech indexes near their 2015 highs, all market cap tiers fell in 4Q18, eliminating the first nine month’s gains and losing $291.2 billion in aggregate value. Median losses...
BioCentury | Jan 11, 2019
Company News

Purdue, Ocular partner to develop non-opioid therapies

Purdue Pharma L.P. (Stamford, Conn.) and Ocular Therapeutix Inc. (NASDAQ:OCUL) will partner to develop and commercialize Purdue's non-opioid new chemical entities with Ocular's bioresorbable hydrogel-based technology. Ocular is responsible for discovery and bringing a product...
BioCentury | Jan 5, 2019
Finance

Ready to launch

The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record year...
BioCentury | Dec 7, 2018
Clinical News

FDA approves Ocular's Dextenza for post-surgery pain

FDA approved Dextenza sustained-release dexamethasone insert from Ocular Therapeutix Inc. (NASDAQ:OCUL) for intracanalicular use to treat ocular pain following ophthalmic surgery. Ocular had received two complete response letters from FDA for Dextenza, the first in...
BioCentury | Oct 6, 2018
Finance

Seeking validation

The final stretch of the year offers clinical catalysts and early launch data that could validate investments in hot immuno-oncology targets and large untapped markets. Late-stage readouts from Vertex Pharmaceuticals Inc. in cystic fibrosis and...
Items per page:
1 - 10 of 96
BioCentury | Aug 17, 2019
Financial News

Aug. 16 Financial Quick Takes: Trio of IPO filings; plus Bellicum, Generex

SpringWorks, Satsuma, Monopar propose IPOs SpringWorks Therapeutics Inc. (Stamford, Conn.), Satsuma Pharmaceuticals Inc. (South San Francisco, Calif.) and Monopar Therapeutics Inc. (Northbrook, Ill.) are looking to go public on NASDAQ. SpringWorks proposed to raise up...
BioCentury | Jul 12, 2019
Company News

July 12 management tracks: Linus Lin joins Lilly’s Chorus; plus Ocular, Aptinyx

Eli Lilly and Co. (NYSE:LLY) named Linus Lin managing director of its Chorus R&D unit. He was previously VP and head of Lilly China Innovation and Partnerships. Eye disease company Ocular Therapeutix Inc. (NASDAQ:OCUL) hired...
BioCentury | Jul 10, 2019
Company News

Management tracks: Maze, Tiaki, NED, Annexon and more

Maze Therapeutics (Redwood City, Calif.) said Richard Scheller joined its board. Scheller, who in January became chairman of R&D at BridgeBio Pharma Inc. (NASDAQ:BBIO), was CSO and head of therapeutics at personal genetics company 23andMe...
BioCentury | May 20, 2019
Clinical News

May 20 Clinical Quick Takes: Keytruda misses in TNBC; plus Medicines Co., Acadia, Takeda, Ocular

Keytruda fails in previously treated TNBC Monotherapy with PD-1 inhibitor Keytruda pembrolizumab from Merck & Co. Inc. (NYSE:MRK) missed the primary endpoint of improving overall survival vs. physician’s choice of single agent chemotherapy in the...
BioCentury | Apr 6, 2019
Finance

Big caps under pressure

Biogen’s fall in the wake of its decision to discontinue late-stage trials of Alzheimer’s therapy aducanumab is yet another reminder that large caps are in dire need of new pipeline products, and could serve as...
BioCentury | Jan 12, 2019
Finance

We all fall down

After an exuberant third quarter that put biotech indexes near their 2015 highs, all market cap tiers fell in 4Q18, eliminating the first nine month’s gains and losing $291.2 billion in aggregate value. Median losses...
BioCentury | Jan 11, 2019
Company News

Purdue, Ocular partner to develop non-opioid therapies

Purdue Pharma L.P. (Stamford, Conn.) and Ocular Therapeutix Inc. (NASDAQ:OCUL) will partner to develop and commercialize Purdue's non-opioid new chemical entities with Ocular's bioresorbable hydrogel-based technology. Ocular is responsible for discovery and bringing a product...
BioCentury | Jan 5, 2019
Finance

Ready to launch

The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record year...
BioCentury | Dec 7, 2018
Clinical News

FDA approves Ocular's Dextenza for post-surgery pain

FDA approved Dextenza sustained-release dexamethasone insert from Ocular Therapeutix Inc. (NASDAQ:OCUL) for intracanalicular use to treat ocular pain following ophthalmic surgery. Ocular had received two complete response letters from FDA for Dextenza, the first in...
BioCentury | Oct 6, 2018
Finance

Seeking validation

The final stretch of the year offers clinical catalysts and early launch data that could validate investments in hot immuno-oncology targets and large untapped markets. Late-stage readouts from Vertex Pharmaceuticals Inc. in cystic fibrosis and...
Items per page:
1 - 10 of 96